Integer Holdings (NYSE:ITGR) today reported fourth-quarter results that beat the consensus forecast on Wall Street, projecting an even better 2022 even as it works through the effects of COVID-19 omicron variant surge.
The Plano, Texas–based medical device contract manufacturing giant earned $23.8 million, or 71¢ per share, off $313.0 million in sales for the quarter ended Dec. 31, 2021, for a bottom-line gain of 54% and sales growth of 16% compared with Q4 2020.
Adjusted to exclude one-time items, earnings per share were 99¢, 13¢ ahead of The Street, where analysts were looking EPS of 86¢ on sales of $307.7 million.
Integer also closed on its $220 million acquisition of Oscor in early December.
Get the full story on our sister site Medical Design & Outsourcing.